Podcast Episode

Chapters

You've been working in gene therapy for a long time now. What do you see as the key learnings of the industry related to bioanalysis of in vivo therapeutic approaches?

6:24

What would you identify as the key commonalities – and the important differences – that exist in approaching bioanalysis of ex vivo gene-modified cell therapies?

9:25

How is the field of gene therapy evolving, and what new therapies and delivery methods do you see on the horizon?

13:43

Why are biodistribution, vector shedding, and transgene expression are such critical factors for ensuring the safety of cell and gene therapies?

15:27

Can you outline the key challenges associated with assessing and monitoring biodistribution and vector shedding?

20:13

What new approaches are being developed to address these challenges? And what impact is that introduction of digital PCR having?

27:18

How can the insights and best practices we've discussed today be applied to specific R&D efforts? What would your key advice be for our listeners who are working in this space?

The BioInsights Podcast

Navigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy development

Jun 09, 2023 Season 2 Episode 6

Paul Byrne

In this episode Róisin McGuigan (Editor, BioInsights) speaks to Paul Byrne (Senior Director, Genomics, ProtaGene) about the evolution of the gene therapy field, with a specific focus on the complexities posed by biodistribution, vector shedding, and transgene expression in gene therapy development.